Strides Pharma Science Ltd (STAR) AI Stock Analysis

• Market Cap: ₹88.71B
• Dividend Yield: 0.42%
• Average Volume (3M): 12.54K
• Price to Earnings (P/E): 22.3
• Beta (1Y): 1.20
• Revenue Growth: 6.22%
• EPS Growth: 123.83%
• Country: IN
• Employees: 3,065
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.84
• Shares Outstanding: 92,172,714
• 10 Day Avg. Volume: 13,417
• 30 Day Avg. Volume: 12,536
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.40
• Price to Sales (P/S): 1.33
• P/FCF Ratio: 13.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ₹1,024.00 ▲(8.14% Upside)

The overall stock score is driven by strong financial performance and positive technical indicators, suggesting a favorable outlook. However, the high P/E ratio and overbought technical signals indicate potential risks, warranting cautious optimism.

Strides Pharma Science Ltd Business Overview & Revenue Model

Company Description

Strides Pharma Science Ltd (STAR) is a global pharmaceutical company headquartered in India, engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates primarily in the sectors of generic pharmaceuticals, contract research and manufacturing services (CRAMS), and over-the-counter (OTC) products. Strides is known for its strong capabilities in the formulation of oral solid doses, injectables, and specialty products, serving both regulated and emerging markets worldwide.

How the Company Makes Money

Strides Pharma Science Ltd generates revenue through multiple key streams, including the sale of generic pharmaceuticals, where it offers a portfolio of high-quality, affordable medications across various therapeutic categories. The company also earns income from contract research and manufacturing services, catering to other pharmaceutical companies by providing outsourced development and production capabilities. Additionally, Strides has established strategic partnerships and collaborations with global firms, enhancing its market reach and boosting revenue through joint ventures and licensing agreements. The company's focus on innovation and product development, particularly in niche markets and specialty therapies, further contributes to its earnings by capturing value in high-demand segments.

Strides Pharma Science Ltd Financial Statement Overview

Summary

Strides Pharma Science Ltd shows a strong recovery in financial performance with improving profitability and cash management. While the income and cash flow statements highlight positive trends, historical volatility and leverage management suggest areas for cautious monitoring.

Income Statement

The income statement shows a strong recovery in net income and revenue growth in the latest period, indicating an improving trajectory. Gross profit margin and net profit margin have significantly improved, reflecting enhanced operational efficiency. However, historical volatility in net income and periods of negative EBIT and EBITDA margins suggest potential risks in maintaining consistent profitability.

Balance Sheet

The balance sheet presents a moderate debt-to-equity ratio, showing a balanced approach to leverage. The return on equity has improved substantially, signaling enhanced shareholder value creation. However, there is room for improvement in optimizing the equity ratio. The company faces challenges in maintaining a healthy cash position and managing liabilities effectively.

Cash Flow

The cash flow statement reflects strong free cash flow generation and positive operating cash flow, indicating solid cash management. The free cash flow to net income ratio suggests good conversion of profit into cash. Yet, fluctuations in free cash flow growth and historical challenges in maintaining consistent cash flows highlight potential risks.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	46.65B	46.24B	38.28B	36.68B	30.70B	32.80B
Gross Profit	19.28B	26.44B	8.51B	8.05B	14.57B	9.59B
EBITDA	9.09B	8.62B	3.76B	5.03B	-1.35B	7.25B
Net Income	3.63B	35.93B	-706.14M	-2.21B	-4.60B	2.68B
Balance Sheet
Total Assets	0.00	60.49B	58.40B	66.38B	69.76B	70.15B
Cash, Cash Equivalents and Short-Term Investments	1.99B	2.06B	2.90B	3.61B	1.84B	2.75B
Total Debt	0.00	18.80B	25.17B	30.30B	30.25B	23.48B
Total Liabilities	-25.86B	34.62B	37.68B	44.66B	45.93B	42.01B
Stockholders Equity	25.86B	25.52B	21.26B	22.12B	23.59B	27.77B
Cash Flow
Free Cash Flow	0.00	4.42B	5.83B	-505.27M	-4.01B	1.84B
Operating Cash Flow	0.00	6.84B	7.01B	444.11M	-2.58B	4.81B
Investing Cash Flow	0.00	-896.89M	-1.50B	3.02B	-1.19B	-5.21B
Financing Cash Flow	0.00	-6.43B	-6.93B	-2.14B	4.21B	-157.96M

Strides Pharma Science Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 946.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:STAR, the sentiment is Positive. The current price of 946.95 is above the 20-day moving average (MA) of 855.42, above the 50-day MA of 859.03, and above the 200-day MA of 766.25, indicating a bullish trend. The MACD of 29.20 indicates Negative momentum. The RSI at 66.30 is Neutral, neither overbought nor oversold. The STOCH value of 69.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:STAR.

Strides Pharma Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	78 Outperform	₹668.50B	19.71	―	0.36%	7.33%	-3.79%
ALKEM	72 Outperform	₹677.34B	29.65	―	0.79%	4.49%	11.22%
STAR	69 Neutral	₹88.71B	22.32	―	0.42%	6.22%	123.83%
LAURUSLABS	66 Neutral	₹530.67B	77.55	―	0.16%	25.83%	421.20%
IPCALAB	60 Neutral	₹335.27B	43.07	―	0.30%	11.49%	35.00%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.14%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Strides Pharma Science Ltd Corporate Events

Strides Pharma Releases Earnings Call Audio for Q2 FY26

Strides Pharma Science Ltd announced the availability of the audio recording of its earnings call discussing the unaudited financial results for the quarter and half year ended September 30, 2025. This move is part of their compliance with SEBI regulations and aims to enhance transparency and communication with stakeholders.

Strides Pharma Releases Earnings Call Audio for Q2 FY26

Strides Pharma Science Limited announced the availability of the audio recording of its earnings call discussing the unaudited financial results for the quarter and half year ended September 30, 2025. This update is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting investor decisions and market perceptions.

Strides Pharma Releases Unaudited Financial Results for September 2025

Strides Pharma Science Limited has released its unaudited financial results for the quarter and half-year ending September 30, 2025. The results, approved by the Board of Directors, were submitted to the stock exchanges in compliance with SEBI regulations. The limited review report by the statutory auditors indicates no material misstatements, reflecting the company’s adherence to Indian Accounting Standards. This announcement is crucial for stakeholders as it provides insights into the company’s financial health and operational performance during the specified period.

Strides Pharma Achieves Record Quarterly EPS in Q2FY26

Strides Pharma Science Ltd reported its highest-ever quarterly earnings per share (EPS) for Q2FY26, with an operational profit after tax (PAT) of ₹1,403 million and an EPS of ₹15.2, marking an 84% year-on-year growth. The company’s strong performance was driven by a 4.6% increase in revenue to ₹12,208 million and a significant improvement in gross and EBITDA margins, reflecting its focus on profitability and financial discipline amidst currency challenges and ongoing capital expenditures.

Strides Pharma Schedules Earnings Call for Q2 2025 Results

Strides Pharma Science Ltd announced that it will hold an earnings call on October 31, 2025, to discuss its unaudited financial results for the quarter and half-year ending September 30, 2025. This call is aimed at providing analysts and investors with insights into the company’s financial performance, which could impact its market positioning and stakeholder interests.